Trials / Recruiting
RecruitingNCT06697665
An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an exploratory clinical study evaluating the safety, tolerability, immune response and preliminary efficacy of LM103 Injection in combination with PD-1 in patients with advanced solid tumours. The research treatment includes LM103 injection, IL-2 therapy, PD-1 therapy,fludarabine and cyclophosphamide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LM103 | Patients were treated with PD-1, cyclophosphamide and fludarabine, LM103 and IL-2 treatment. |
Timeline
- Start date
- 2024-01-23
- Primary completion
- 2026-01-01
- Completion
- 2027-06-01
- First posted
- 2024-11-20
- Last updated
- 2024-11-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06697665. Inclusion in this directory is not an endorsement.